News
Source-attributed headlines with timestamps and links to the companies and crypto markets they mention.
Latest Coverage
30 headlines
A new, exclusive loyalty relationship launching in the coming months will bring together Delta SkyMiles and World of Hyatt programs to help connect the air and hotel experience for their most loyal customers. Initial
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.
https://www.bloomberg.com/news/articles/2026-09-09/jefferies-fund-wins-singapore-asset-freeze-against-radiant-world
UBS analyst Mark Carden maintains United Natural Foods (NYSE:UNFI) with a Neutral and raises the price target from $47 to $50.
https://www.apple.com/apple-events/event-stream/
Legal AI startup Harvey has raised $550 million at a $15.5 billion valuation, more than tripling its customer base since March.
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.
UBS analyst Josh Silverstein maintains SLB (NYSE:SLB) with a Buy and raises the price target from $66 to $72.
UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.
https://www.apple.com/apple-events/event-stream/
Raymond James analyst J.R. Weston maintains Solaris Energy Infr (NYSE:SEI) with a Outperform and raises the price target from $82 to $96.
UBS analyst Doug Schenkel maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $290 to $435.
Needham analyst Ryan MacDonald reiterates Barnes & Noble Education (NYSE:BNED) with a Buy and maintains $16 price target.
Raymond James analyst John Freeman maintains Expand Energy (NASDAQ:EXE) with a Strong Buy and raises the price target from $145 to $147.
BTIG analyst Gray Powell reiterates SailPoint (NASDAQ:SAIL) with a Buy and maintains $21 price target.
UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.
Filed: 2026-09-09 AccNo: 0001325814-26-000142 Size: 184 KB Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
https://www.apple.com/apple-events/event-stream/
Raymond James analyst Brian Peterson maintains Braze (NASDAQ:BRZE) with a Outperform and raises the price target from $27 to $33.
UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.
HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.
Robinhood CEO Vlad Tenev defends 1:1 backed stock tokenization as Needham analysts signal a crypto bottom and long-term growth potential for HOOD.
Cipher Digital (CIFR) drops 8% to $16.99 amid market drag. Key technical levels: $16 support and $18 resistance.